Immutep Limited (ASX:IMM) Insider Marc Voigt Buys 29,500 Shares

Immutep Limited (ASX:IMM) insider Marc Voigt bought 29,500 shares of the business’s stock in a transaction dated Wednesday, September 18th. The shares were acquired at an average cost of A$0.34 ($0.23) per share, with a total value of A$10,030.00 ($6,869.86).

Immutep Stock Performance

The company has a debt-to-equity ratio of 0.84, a quick ratio of 13.78 and a current ratio of 18.25.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.